Clinical trials of new antimicrobials, antiviral (non-HIV), and antifungals, phase 1-4, focusing on new agents for multi-drug-resistant pathogens.

Computer modeling of antimicrobial drug exposure, based on concepts of pharmacokinetics/pharmacodynamics, integrating MIC frequency distributions in simulations to predict clinical and microbiologic success in treatment of infections in different body compartments.

Longitudinal Assessment of Beta-lactam Antibiotic Exposure in in Critically Ill Children with Sepsis (5R01HD095547-02)

Clinical trial design and regulatory science (a member of the FDA’s Advisor and Consultant’s Staff)